secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0000950170-24-129238
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo
-------------------------------------------------------------------------

- PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.
- Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.
- Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.
- PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.
- Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/0000950170-24-129238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024129238/pyxs-20241120.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-129238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer